Imatinib-induced regression of AIDS-related Kaposi's sarcoma.

PURPOSE Activation of the platelet-derived growth factor (PDGF) and c-kit receptors has been proposed as important in mediating the growth of AIDS-related Kaposi's sarcoma (KS). We investigated the response of KS to the PDGF receptor (PDGFR)/c-kit inhibitor, imatinib mesylate, and investigated the effect of this therapy on critical signal transduction intermediates. PATIENTS AND METHODS Ten male patients with AIDS-related cutaneous KS, which progressed despite chemotherapy and/or highly active antiretroviral therapy, received imatinib mesylate administered orally, 300 mg twice daily. Clinical response was determined by serial tumor measurements. To determine biologic and histologic response, skin lesion biopsies were obtained at baseline and following 4 weeks of therapy. RESULTS Five of 10 participants had a partial response by tumor measurements. Biopsies after 4 weeks of therapy demonstrated histologic regression in four of six patients. Four patients' tumor biopsies were assessable for immunohistochemistry end points pre- and post-therapy. These demonstrated inhibition of PDGFR and its downstream effector, extracellular receptor kinase, which is a member of the mitogen-activated protein kinase family. The most common adverse event was diarrhea, which led to dose reduction in six patients. CONCLUSION Imatinib mesylate administered orally twice daily for AIDS-related KS results in clinical and histologic regression of cutaneous KS lesions within 4 weeks. These promising results demonstrate that inhibition of the c-kit and/or PDGF receptors may represent an effective strategy for treating KS.

[1]  L. Pantanowitz,et al.  Histological characterization of regression in acquired immunodeficiency syndrome‐related Kaposi's sarcoma , 2004, Journal of cutaneous pathology.

[2]  M. Egorin,et al.  Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. , 2003, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[3]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[4]  J. Eary,et al.  Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[6]  B. Druker,et al.  Kaposi's Sarcoma-Associated Herpesvirus-Induced Upregulation of the c-kit Proto-Oncogene, as Identified by Gene Expression Profiling, Is Essential for the Transformation of Endothelial Cells , 2002, Journal of Virology.

[7]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[8]  L. Chaudhary,et al.  The cell survival signal Akt is differentially activated by PDGF‐BB, EGF, and FGF‐2 in osteoblastic cells , 2001, Journal of cellular biochemistry.

[9]  Yueqin Liu,et al.  The Role of Phosphatidylinositol 3-Kinase and the Mitogen-Activated Protein Kinases in Insulin-Like Growth Factor-I-Mediated Effects in Vascular Endothelial Cells. , 2001, Endocrinology.

[10]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[11]  J. Griffin,et al.  Bcr/Abl activates transcription of the Bcl-X gene through STAT5. , 2000, Blood.

[12]  L. Chaudhary,et al.  Extracellular‐signal regulated kinase signaling pathway mediates downregulation of type I procollagen gene expression by FGF‐2, PDGF‐BB, and okadaic acid in osteoblastic cells , 2000, Journal of cellular biochemistry.

[13]  F. Gouilleux,et al.  Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line , 2000, Oncogene.

[14]  T. Hunter,et al.  The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 , 1998, Current Biology.

[15]  T. Dexter,et al.  Investigation of the molecular mechanisms underlying growth factor synergy: the role of ERK 2 activation in synergy. , 1998, Growth factors.

[16]  J. Baldassare,et al.  Ras-stimulated Extracellular Signal-related Kinase 1 and RhoA Activities Coordinate Platelet-derived Growth Factor-induced G1 Progression through the Independent Regulation of Cyclin D1 and p27KIP1 * , 1997, The Journal of Biological Chemistry.

[17]  B. Groner,et al.  Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. , 1997, Immunity.

[18]  R. Masood,et al.  Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Tschachler,et al.  Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. , 1996, The American journal of pathology.

[20]  C. Flaitz,et al.  Herpesviridae-associated persistent mucocutaneous ulcers in acquired immunodeficiency syndrome. A clinicopathologic study. , 1996, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[21]  P. Biberfeld,et al.  A role for a new herpes virus (KSHV) in different forms of Kaposi's sarcoma , 1995, Nature Medicine.

[22]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[23]  P. Hofschneider,et al.  Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. , 1995, Oncogene.

[24]  P. Hofschneider,et al.  Expression of platelet-derived growth factor and its receptor in AIDS-related Kaposi sarcoma in vivo suggests paracrine and autocrine mechanisms of tumor maintenance. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Miles.  Kaposi sarcoma: a cytokine-responsive neoplasia? , 1992, Cancer treatment and research.

[26]  L. Brandt,et al.  Gastrointestinal malignancy in patients with AIDS. , 1991, The American journal of gastroenterology.

[27]  T. Hirano,et al.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Krown,et al.  Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Hofschneider,et al.  Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. , 1989, Oncogene.

[30]  S. Nakamura,et al.  AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. , 1989, Science.

[31]  S. Krown,et al.  Kaposi's Sarcoma in the Acquired Immune Deficiency Syndrome: A Proposal for Uniform Evaluation, Response, and Staging Criteria , 1989 .

[32]  Ralph,et al.  A Clinicopathologic Study , 2006 .